Logo

Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Share this
Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-II CodeBreaK 100 trial evaluating the efficacy and tolerability of Lumakras (PO- qd) in 126 patients with KRAS G12C mutation-positive advanced NSCLC whose disease had progressed after prior treatment with immunotherapy or CT
  • The 1EPs were centrally assessed ORR. Additionally- the therapy demonstrated a positive benefit-risk profile with rapid- deep- and durable anticancer activity
  • The therapy is also being studied in multiple other solid tumors. The company has completed enrollment in the P-III CodeBreaK 200 study for sotorasib vs docetaxel in patients with the same indication & results of the P-II trial in CRC is expected in later 2021

  | Ref: Newswire Canada | Image: BioSpace

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions